Hengrui Pharma's (01276) self-developed CDK4/6 inhibitor, dalpiciclib hydroxyethanesulfonate tablets, has received approval from the National Medical Products Administration (NMPA) for a new indication.

Hengrui Pharma (01276) announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereinafter referred to as the "Company") recently received notification from the National Medical Products Administration (hereinafter referred to as the "NMPA"), approving a new indication for dalpiciclib hydroxyethanesulfonate tablets, a CDK4/6 inhibitor independently developed by the Company.

Zhitong FinanceJun 16 22:13

Hengrui Pharma (01276): SHR-6914 Injection Receives Clinical Trial Approval Notice

Hengrui Pharma (01276) announced that recently, Suzhou Sondia Biopharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Medicine Co., Ltd. (hereinafter referred to as the "Company"), received a "Notice of Approval for Drug Clinical Trial" from the National Medical Products Administration (hereinafter referred to as the "NMPA") regarding SHR-6914 Injection, and will commence clinical trials shortly.

Zhitong FinanceJun 16 21:26

Hengrui Pharma (01276.HK): "HRS-7525 Tablets" Granted Approval for Clinical Trials

Gelonghui, June 16 — Hengrui Pharma (01276.HK) announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd. has recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration regarding HRS-7525 tablets and will initiate clinical trials shortly. Drug Name: HRS-7525 Dosage Form: Tablet Application Type: Clinical Trial Acceptance Numbers: CXHL2600319, CXHL2600320 Approval Conclusion: Pursuant to the Drug Administration Law of the People's Republic of China and relevant regulations, following review, the application for HRS-7525 submitted on March 12, 2026

Gelonghui FinanceJun 16 21:20

JPMorgan upgraded Hengrui Pharma to Overweight due to its valuation and growth prospects.

Gelonghui, June 16 | JPMorgan upgraded the Hong Kong-listed shares of Hengrui Pharma to Overweight, citing attractive valuation, sustained earnings improvement, and rapidly increasing pipeline value. Analysts including Yang Huang wrote in a research report: “The recent share price decline stems from macro-level headwinds, including heightened geopolitical tensions and broad-based institutional selling of Hong Kong healthcare assets to reduce risk exposure; this downturn reflects a sector-wide valuation reset rather than company-specific pressure.” Given that escalating geopolitical conflicts could affect future out-licensing deals for innovative drugs, institutions have revised downward their forecasts for the company’s external collaboration and licensing revenue.

Gelonghui FinanceJun 16 08:25

Guotai Haitong: Citing the high景qi (favorable conditions) in the innovative pharmaceuticals sector, strong fundamentals among listed companies, and low valuations, we remain bullish on the development of China's innovative pharmaceuticals industry.

The Innovative Drug Index has fallen back to the level seen before the previous rally in innovative drug stocks began (May 2025), highlighting its attractive valuation.

Zhitong FinanceJun 16 07:14

Billions in Share Buybacks to Stabilize Markets? As Stock Prices Remain Weak, Leading Pharmaceutical Firms Launch a 'Valuation Defense Campaign'

① Amid sustained downward pressure on share prices, several pharmaceutical companies—including Sino Biopharm, Akeso, and Wuxi Apptec—have successively announced share repurchase or management buy-in plans; ② Industry insiders believe that such repurchases can help restore market sentiment, but a meaningful re-rating of the sector will still depend on the consistent realization of commercialization and global expansion capabilities.

cls.cnJun 15 17:06